[
    "{\"step_by_step_thinking\": \"Ivosidenib is mentioned in several documents as a treatment for acute myeloid leukemia (AML). Document [0] states that the FDA approved ivosidenib for patients with IDH1-mutant relapsed/refractory acute myeloid leukemia. Document [1] also mentions that ivosidenib is a promising new drug for the treatment of IDH1-mutated AML. Document [4] further confirms that ivosidenib was approved in the United States for relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation.\", \"answer_choice\": \"A\"}"
]